Renal replacement therapy in Poland and worldwide by Fortuna-Kawalec, Iwona et al.





Abstract – Introduction. The first hemodialysis in Poland was 
performed on 6 November 1958 in Poznań. An attempt to save 
the life of a 38-year-old man with acute kidney failure was a suc-
cess. At that time, only patients with life-threatening conditions 
caused by conduction, hypercalemia, severe respiratory acidosis 
or severe uremic toxemia were qualified for haemodialysis treat-
ment.  
Aim of the study. The aim of the study was to present a brief 
historical outline of renal replacement therapy in Poland and 
worldwide, to characterise haemodialysis as a method of renal 
replacement therapy and to discuss indications for renal replace-
ment therapy.  
Selection of material. The search was conducted in the Scopus 
database for the period 2002-2019, using the concepts of history 
of renal replacement therapy, hemodialysis, indications for renal 
replacement therapy. From the literature found in the Google 
Scholar database, studies were selected which, in the opinion of 
the authors, would be most useful in the preparation of this study.  
Conclusions. Kidneys are an extremely important organ. They 
have the ability to regulate the amount of diuresis, relative con-
centration and density and the chemical composition of urine. 
This allows them to maintain the water-electrolyte and acid-base 
balance. They also play an important role in hormonal regulation 
of arterial pressure and red blood cell production. When the kid-
neys stop functioning, the concentration of substances normally 
excreted in urine, such as urea and creatinine, which are produced 
as waste in biochemical processes, increases rapidly in the blood, 
then renal replacement methods are necessary.  
 
Key words - history of renal replacement therapy, hemodialysis, 
indications for renal replacement therapy.  
 
Streszczenie – Wstęp. Pierwszą w Polsce hemodializę wykonano 
6 listopada 1958r. w Poznaniu. Sukcesem zakończyła się próba 
uratowania życia 38- letniego mężczyzny z ostrą niewydolnością 
nerek. Do leczenia hemodializami kwalifikowano wówczas 
wyłącznie chorych w stanie zagrożenia życia, spowodowanego 
przewodnieniem, hiperkaliemią, ciężką kwasicą oddechową lub 
nasiloną toksemią mocznicową.  
Cel pracy. Celem pracy było przedstawienie krótkiego rysu  his-
torycznego leczenia nerkozastępczego w Polsce i na świecie, 
scharakteryzowania hemodializy jako metoda leczenia  
 
 
nerkozastępczego oraz omówienia wskazań do leczenia 
nerkozastępczego.  
Dobór materiału. Poszukiwania przeprowadzono w bazie Scopus 
za okres 2002-2019, używając pojęć historia leczenia 
nerkozastępczego, hemodializa, wskazania do leczenia 
nerkozastępczego. Ze znalezionego w bazie Google Scholar 
piśmiennictwa wyselekcjonowano opracowania, które zdaniem 
autorów byłyby najbardziej użyteczne w przygotowaniu 
niniejszego opracowania.  
Wnioski. Nerki są niezwykle ważnym narządem. Mają zdolność 
regulowania wielkości diurezy, stężenia i gęstości względnej oraz 
składu chemicznego moczu. Dzięki temu służą do zachowania 
równowagi wodno-elektrolitowej i kwasowozasadowej. Od-
grywają również dużą rolę w regulacji hormonalnej ciśnienia 
tętniczego oraz produkcji krwinek czerwonych. Gdy nerki 
przestają funkcjonować, we krwi szybko rośnie stężenie sub-
stancji normalnie wydalanych z moczem jak na przykład mocz-
nik i kreatynina, które w przemianach biochemicznych powstają 
jako odpady, wówczas konieczne jest zastosowanie metod 
nerkozastępczych. 
 
Słowa kluczowe - historia leczenia nerkozastępczego, hemodiali-
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I. SHORT HYSTERICAL FEATURES 
 
 
he pioneer of dialysis was Georg Hass of Giessen, who 
was the first to carry out dialysis in humans using hep-
arin to treat poisoning in 1928. The first blood purifi-
cation procedure in the course of acute renal failure was 
carried out by Prof. Willem Kolf from Kampen (the Neth-
erlands), who in 1945, using repeated haemodialysis, man-
aged to keep a 68-year-old woman alive until her kidney 
function returned [1].  
In 1950 the first dialysis department was opened in Swe-
den by Prof. Alwall. It was him who created the devices, 
which at the end of the 1950s came to Poland. Prof. Jan 
Roguski from the Clinic of Internal Medicine of the Medi-
cal University of Poznań and Prof. Andrzej Biernacki from 
the 1st Clinic of Internal Medicine of the Medical Univer-
sity of Warsaw tried to buy them [2].  
The first hemodialysis in Poland was performed on 6 
November 1958 in Poznań. An attempt to save the life of a 
38-year-old man with acute kidney failure was a success. 
At that time, only patients with life-threatening conditions 
caused by conduction, hypercalemia, severe respiratory 
acidosis or severe uremic toxemia were qualified for hae-
modialysis treatment. The treatment lasted from 10 to 12 
hours, and the preparation of the device over 24 hours with 
the necessity to cook it at the end, because it was the only 
way to sterilise the device. As many as four nurses were 
involved in the preparation of the device. It was a hard 
physical work because the drums on which the cellophane 
dialysis membrane was wound were very important. For 
haemodialysis, tap water was used without treatment, 
which posed a pyrogenic threat, so the patient was con-
stantly observed for the appearance of dialysis reactions 
[3]. Despite difficulties, until January 2, 1959, when the 
first haemodialysis was performed in Warsaw, 14 proce-
dures were performed in Poznań. In the same year, 81 
haemodialysis procedures were carried out in Poznań and 
56 in Warsaw. The situation improved in 1961, when hae-
modialysis started in the Department of Internal Medicine 
of the Military Medical Academy in Łódź. A year later, the 
Second Clinic of Internal Diseases of the Medical Univer-
sity of Krakow joined the haemodialysis centres. In 1964, 
in the Second Clinic of Internal Medicine in Gdansk, he-
modialysis therapy with a new type of apparatus - gangli-
onic kidney constructed by Wilhelm Kolff and Bruno 
Watschinger was started. The advantage of this model was 
reduced to 800 ml volume of blood necessary to fill the 
apparatus before activation, compared to 1.5-2 litres of 
blood used in Alwall apparatus [4].  
In Poland, domestic manufacturers have made attempts 
to produce dialysis equipment, but due to the great unrelia-
bility of the materials, they could not compete with a pro-
totype competing with foreign products. The closest to 
success was Famed in Lodz, whose HD100 apparatus was 
produced until 1993. The number of new haemodialysis 
centres was gradually increasing [2]. At the end of 1970s 
there were already 39 nephrological centres in Poland. 
Newer devices of the Bellco 714 and Gambro AK5 com-
pany appeared. Thanks to the use of factory-folded gangli-
onic dialyzers, the duration of hemodialysis was reduced to 
5-6 hours. Hemodialysis procedures were very expensive, 
therefore, for economic reasons, all dialysis stations used 
dialyzers again [3]. One of the key problems in haemodial-
ysis was the lack of permanent vascular access. In 1959, a 
milestone was the development of a dual-lumen silastic 
catheter, which was introduced to the femoral vein using 
the Seldinger method for repeated dialysis. In 1960 sur-
geons from Seattle developed a system of cannulation of 
arterial and venous vessels introducing Teflon endings 
connected with silastic drains, brought to the skin and con-
nected to each other. They were used on vessels in the an-
kle or wrist area [4]. At the beginning of hemodialysis, the 
silastic arch was disconnected and after the treatment it 
was connected again. The fistula was named Scribner - 
Quinton after its originator and producer. Despite frequent 
complications in the form of clots and infections, for the 
first time it gave the possibility of permanent dialysis.  
The breakthrough stage in the history of vascular access 
was the first ever subcutaneous arterio-venous fistula per-
formed by a team of surgeons from New York City, Ci-
minio and Brescia in 1965, which type of access is still 
dominant today [5].  
The 1980s saw a breakthrough in Poland in the creation of 
new centres and the modernisation of dialysis equipment. 
This was connected with the establishment in 1984. In 
1984, the National Specialist Team for Dialysis and Kid-
ney Transplantation was established, which two years later 
was transformed into the National Specialist Team for 
Nephrology. Water treatment equipment was installed in 
all centres. Capillary dialyzers with a large dialysis area 
were introduced, which reduced the duration of hemodial-
ysis to 4-5 hours 3 times a week. Automatic reutilization 
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was started, which limited the harmful effects of sterilizers 
and facilitated the work of nursing personnel [3]. Signifi-
cant technical progress resulted in a significant increase in 
effectiveness of the therapy offered to patients [6].  
The year 1992 was of great importance in the develop-
ment of hemodialysis in Poland, when the "Programme for 
Improvement and Development of Dialysis" developed by 
the National Team of Medical Consultants in Nephrology 
[7] was implemented. Today's hemodialyses undoubtedly 
do not resemble those of several years ago. The knowledge 
of medical personnel about the process of dialysis allows 
to carry out treatments that are increasingly safe, with few-
er complications than in the past [8]. 
 
 




Renal replacement therapy is understood to mean meth-
ods of therapy that replace the functions of the damaged 
kidneys. These include dialysis therapy, i.e. hemodialysis 
and peritoneal dialysis [9].  
Kidneys are an extremely important organ. They have 
the ability to regulate the amount of diuresis, relative con-
centration and density and the chemical composition of 
urine. This allows them to maintain the water-electrolyte 
and acid-base balance. They also play an important role in 
hormonal regulation of arterial pressure and red blood cell 
production [10]. When the kidneys stop functioning, the 
concentration of substances normally excreted in urine, 
such as urea and creatinine, which are produced as waste 
in biochemical transformations, increases rapidly in blood. 
Then the task of the inactive kidney is usually taken over 
by the "artificial kidney". The procedure involving it is 
hemodialysis, i.e. blood washing [11].  
Haemodialysis is an extracorporeal dialysis. During the 
procedure blood is collected from the patient by means of 
vascular access and then flows through sterile plastic 
drains and a filter, i.e. a dialyzer, which is connected to the 
apparatus and cleansed returns to the patient. The dialyzer 
contains up to 10000 thin capillaries made of semi-
permeable membrane. There is blood flowing inside the 
capillaries and outside the dialysis fluid [12]. The process 
of exchange between the patient's blood and the dialysis 
fluid of water and substances soluble in it takes place. The 
composition of the dialysis fluid is selected so that toxic 
products of metabolism get into it from plasma, and sub-
stances from the dialysis fluid which are lacking in the 
patient's body are delivered to plasma. These include bi-
carbonates and calcium. The exchange of substances is 
possible due to diffusion and convection processes, i.e. 
ultrafiltration [13].  
Diffusion is the movement of plasma soluble molecules 
through pores of sufficient size in the semipermeable 
membrane to the dialysis fluid and vice versa 9 according 
to a concentration gradient. With the completion of hemo-
dialysis, the exchange rate decreases, which is associated 
with the decrease in concentration difference on both sides 
of the membrane [14]. It is very important that during the 
procedure, as much blood as possible is in contact with the 
dialysis membrane. This is influenced by the dialyser sur-
face and appropriate blood flow. The volume of blood ex-
pelled during the procedure should be at least equal to the 
dry mass of the patient, then the dialysis is adequate [15].  
Convection is the process of transporting a solvent and 
substances dissolved in it through a semi-permeable mem-
brane under the influence of differential pressure. Thanks 
to their small size, water molecules permeate through all 
types of semi-permeable membranes, therefore, through 
ultrafiltration the excess of fluids accumulated by the pa-
tient in the period between dialysis is removed [16].  
Dialysis patients are examined on a monthly basis. The 
results determine whether the treatments are sufficient and 
whether additional drugs are not required. Depending on 
the results, the duration of the procedure is increased, as 
well as blood flow. Most often haemodialysis takes place 3 
times a week for about 4 hours and the blood flow rate is 
250- 450ml/min [17]. According to the data of the Polish 
Nephrological Society in 2016, a total of 20144 people 
were dialysed, including 19192 by haemodialysis and 952 
by peritoneal dialysis. Men dominated among patients, 
representing 58%. [18]. Haemodialysis is the most fre-
quently used method of renal replacement therapy. It dom-
inates in end-stage therapy and acute renal failure in adults, 
and in children it is used in less than 1% of cases, peritone-
al dialysis is more frequent [19].  
 
 




Kidneys are considered healthy as long as they are 
properly filtered and there are no signs of protein or blood 
in the urine. The degree of filtration, i.e. glomerular filtra-
tion (GFR), depends on many factors that affect kidney 
function. The basis for checking the size of glomerular 
filtration is a laboratory test [20].  
Dialysis should be started when GFR is less than 
10ml/min/1.73m2 of body surface. Urea level above 250 
mg/dl is also an indication. In addition to assessing the size 




of urea toxins, it is extremely important to determine the 
level of potassium, which should not be higher than 6.5 
mmol/l, and to determine the degree of metabolic acidosis, 
as stated by the level of total bicarbonates, which should 
not be lower than 13 mmol/l. In the case of persons with 
the diagnosis of diabetic nephropathy, renal replacement 
therapy is initiated much earlier, when the GFR is below 
20 ml/min/1.73m2 of body surface area [21]. It is also im-
portant to assess the patient's clinical condition in terms of 
weight loss combined with significant appetite reduction, 
nausea and vomiting [22].  
Dialysis treatment can be divided into periodic treat-
ment, which includes patients with acute renal failure and 
continuous treatment in patients with chronic end-stage 
renal failure [23].  
Acute kidney failure (AKF) is a disease syndrome that is 
often reversible, caused by a sudden deterioration in kid-
ney function, which leads to insufficient excretion of met-
abolic products from the body and large electrolyte and 
water metabolism disorders. The deterioration of renal 
blood supply, damage to the renal parenchyma or abnormal 
urinary excretion may contribute to AKF [24]. Kidney 
failure can also occur as a result of antibiotic treatment 
against infectious endocarditis [25]. Acute renal failure is 
diagnosed when serum creatinine concentration increases 
above 26.3μmol/l in 48 hours, or creatinine concentration 
increases 1.5 times the upper limit of the norm, which oc-
curs within a week, or when diuresis is less than 0.5 
ml/kg/h for another 6 hours [26]. Acute renal failure mani-
fests itself in stomach or urinelessness, and later in polyu-
ria, as well as blood clotting disorders, anaemia, arrhyth-
mia and difficulty in breathing. Loss of appetite, drowsi-
ness, weakness, irritability and disorientation may also 
occur [27].  
Chronic kidney failure is a disease syndrome that occurs 
gradually with permanent impairment of kidney function. 
The disease cannot be cured, but its progress can be 
slowed down [28]. There are five stages of the disease. In 
the first four stages, treatment focuses on maintaining kid-
ney function. Unfortunately, the disease is often detected 
in the last stage when it is necessary to start dialysis thera-
py [29]. Initially, the symptoms are not noticeable. Only in 
the third stage, when kidney function is reduced by 30 - 
60% from normal values, it is necessary to take medicines 
and follow a diet to delay the next stages. In the fourth 
stage, the kidneys lose up to 90% of their filtering capacity 
and this is stage 11 of preparations for haemodialysis or, if 
there are no contraindications, for transplantation [30]. As 
the disease progresses, there are more and more worrying 
symptoms. The smell of ammonia from the mouth or dry-
ness and metallic taste are characteristic. The skin becomes 
dry yellowish and itchy. Oral and gum inflammation, skin 
and mucous membrane cyanosis and gastrointestinal bleed-
ing may occur [31]. As a result of reduced urine volume, 
arterial pressure increases and swelling occurs. Heart fail-
ure and arrhythmias appear. Pulmonary oedema, pulmo-
nary fibrosis and pneumonia or pleuritis may occur [32]. In 
patients with chronic renal failure, decreased immunity and 
increased glucose and lipid concentrations are observed. 
Moreover, hormonal disorders, hyperparathyroidism and 
disorders of the skeletal and nervous systems, as well as 
disorders of blood morphology and ionic-acid balance may 
also occur [33].  
In older people, diabetic nephropathy, hypertensive 
nephropathy and ischemic atherosclerotic nephropathy are 
the main causes of end-stage renal failure [34]. The causes 
also include glomerulonephritis, which accounts for 20% 
of cases, and interstitial nephritis, chronic pyelonephritis 
and cystic kidneys [35].  
In chronic kidney disease, complex mineral-bone disorders 
occur, which increases the risk of bone fractures [36]. The 
disease is a factor accelerating the process of deceleration 
at any age, and its early diagnosis reduces the degree of 
physical and cognitive disability [37].  
End stage renal failure contributes to the risk of death and 
cardiovascular complications [38]. In the world, about 10-
15% of people suffer from chronic kidney disease. In Po-
land, it is estimated that there are about 4 million patients, 
many of whom may not yet be aware of it, as the disease 
develops slowly and asymptomatic [39]. Contraindications 
for renal replacement therapy are primarily lack of consent 
for treatment with dialysis, as well as severe systemic dis-
eases such as permanent brain damage and dementia and 
disseminated cancer combined with lack of awareness and 
immobilisation in bed. In such situations, the initiation of 
dialysis treatment would contribute to a deterioration in the 
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